表达载体市场 - 全球产业规模、份额、趋势、机会和预测，按宿主类型、应用、最终用户、地区和竞争细分，2020-2030F

2024 年全球表达载体市场价值为 4.405 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2030 年的复合年增长率为 5.10%。表达载体是一种 DNA 分子，用于生物技术和分子生物学，在宿主细胞内携带和表达特定基因。表现载体旨在促进其携带的基因产生蛋白质或其他基因产物。它们作为分子载体将外来遗传物质（例如，感兴趣的基因）引入宿主细胞，在宿主细胞中，基因可以被转录和翻译以产生功能性蛋白质。表现载体含有启动子区，它是作为启动基因转录的开关的特定 DNA 序列。

启动子通常根据其强度和特异性进行选择，取决于所需的基因表现水平和宿主细胞的类型。表达载体具有复製起点，它是宿主细胞的复製机制识别的 DNA 序列。此序列允许载体在宿主细胞内复製和繁殖，确保引入的基因在细胞分裂过程中传递给子细胞。

主要市场驱动因素

基因治疗扩展

主要市场挑战

安全问题

主要市场趋势

环境永续性

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球表达载体市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依宿主类型（细菌表达载体、哺乳动物表达载体、昆虫表达载体、酵母表达载体、其他）
  • 按应用（治疗、研究、其他）
  • 按最终用户（製药和生物技术、学术研究、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太表达载体市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲表达载体市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美表达载体市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第九章：南美表达载体市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲表达载体市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球表达载体市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Thermo Fisher Scientific, Inc.
• Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics Inc.
• Addgene, Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Expression Vector Market was valued at USD 440.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.10% through 2030. An expression vector is a type of DNA molecule used in biotechnology and molecular biology to carry and express specific genes within host cells. Expression vectors are designed to facilitate the production of proteins or other gene products from the genes they carry. They serve as molecular vehicles for introducing foreign genetic material (e.g., a gene of interest) into host cells, where the gene can be transcribed and translated to produce a functional protein. Expression vectors contain a promoter region, which is a specific DNA sequence that acts as a switch to initiate gene transcription.

Promoters are often chosen based on their strength and specificity, depending on the desired level of gene expression and the type of host cell. Expression vectors have an origin of replication, which is a DNA sequence recognized by the host cell's replication machinery. This sequence allows the vector to replicate and propagate inside the host cell, ensuring that the introduced gene is passed on to daughter cells during cell division.

Key Market Drivers

Gene Therapy Expansion

Expression vectors serve as crucial gene delivery vehicles in gene therapy. They are used to transport therapeutic genes into target cells, facilitating the correction of genetic defects or the introduction of therapeutic genes to treat various diseases. Gene therapy has expanded beyond rare diseases to include a wide range of therapeutic applications, such as cancer treatment, genetic disorders, neurological diseases, and cardiovascular conditions. Each application may require tailored expression vectors to achieve optimal gene delivery and expression. The increasing number of gene therapy clinical trials and the approval of gene therapies by regulatory agencies drive demand for expression vectors. These vectors are essential for producing therapeutic genes used in clinical studies and commercialized treatments. Gene therapy research often demands customized expression vectors. Researchers and biotech companies may require vectors that are specific to their therapeutic targets, ensuring precise gene delivery and appropriate expression levels. Many gene therapies rely on viral vectors, such as adeno-associated virus (AAV) vectors and lentiviral vectors, for gene delivery. The development and commercialization of viral vector-based gene therapies have led to a surge in demand for these vectors. For instance, according to the World Health Organization (WHO) in 2021, non-communicable diseases (NCDs) account for 41 million deaths annually, representing 71% of all global deaths. Over 15 million people aged 30 to 69 die each year from NCDs, highlighting their significant impact on public health worldwide.

Key Market Challenges

Safety Concerns

Expression vectors, particularly those used in gene therapy and biopharmaceutical production, must adhere to strict biosafety regulations. Ensuring that vectors do not pose risks to human health, or the environment is essential. Biosafety levels and containment measures are established to prevent accidental release or exposure to genetically modified organisms (GMOs) and biohazardous materials. The use of expression vectors for gene editing, such as CRISPR-Cas9 technology, raises concerns about off-target effects and unintended genetic modifications. Ensuring the precision and safety of gene editing procedures is a critical challenge. The release of genetically modified organisms into the environment, even unintentionally, can have ecological consequences. Proper containment and disposal methods are necessary to prevent environmental contamination. In gene therapy, the integration of expression vectors into the host genome may pose long-term safety risks. Insertional mutagenesis, where vector integration disrupts normal gene function, is a concern. In biopharmaceuticals, the presence of vector-related proteins or antigens in therapeutic products can trigger an immune response in patients, leading to safety issues and reduced efficacy. Achieving tissue-specific expression using expression vectors is challenging but critical for minimizing off-target effects and ensuring safety in gene therapy applications. Viral vectors used in gene therapy can trigger immune responses in patients. Strategies to mitigate vector immunogenicity are essential to improve safety and therapeutic efficacy.

Key Market Trends

Environmental Sustainability

Biotechnology companies are increasingly adopting green bioprocessing practices that reduce the environmental impact of expression vector production. This includes optimizing fermentation processes to minimize waste, energy consumption, and resource use. There is a growing demand for expression vector systems that are environmentally friendly. Companies are developing vector systems that use fewer resources and generate less waste during production. Research and development efforts are focused on creating biodegradable vectors that break down naturally after use, reducing the environmental burden of vector disposal. Companies are exploring sustainable sourcing of raw materials used in vector production, such as growth media components, to reduce the environmental footprint of vector manufacturing. Investments in energy-efficient biomanufacturing processes and facilities are becoming more common. This reduces energy consumption during vector production and contributes to sustainability goals. Sustainable practices aim to minimize waste generation throughout the vector production process. This includes recycling and reusing materials when possible. Companies are taking steps to measure and reduce the carbon footprint associated with vector production and distribution. This may involve using renewable energy sources and optimizing transportation logistics.

Key Market Players

• Thermo Fisher Scientific, Inc.,
  • Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics
• Addgene, Inc.

Report Scope:

In this report, the Global Expression Vector Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Expression Vector Market, By Host Type:

• Bacterial expression vectors
• Mammalian expression vectors
• Insect expression vectors
• Yeast expression vector
• Others

Expression Vector Market, By Application:

• Therapeutic
• Research
• Others

Expression Vector Market, By End-User:

• Pharmaceutical & biotech
• Academic research
• Others

Expression Vector Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Expression Vector Market.

Available Customizations:

Global Expression Vector Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Expression Vector Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Host Type (Bacterial expression vectors, Mammalian expression vectors, Insect expression vectors, Yeast expression vector, Others)
  • 5.2.2. By Application (Therapeutic, Research, Others)
  • 5.2.3. By End User (Pharmaceutical & biotech, Academic research, Others),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Expression Vector Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Host Type
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Expression Vector Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Host Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. India Expression Vector Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Host Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Australia Expression Vector Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Host Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User
  • 6.3.4. Japan Expression Vector Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Host Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End-User
  • 6.3.5. South Korea Expression Vector Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Host Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End-User

7. Europe Expression Vector Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Host Type
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Expression Vector Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Host Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. Germany Expression Vector Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Host Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. Spain Expression Vector Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Host Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Expression Vector Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Host Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. United Kingdom Expression Vector Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Host Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. North America Expression Vector Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Host Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Expression Vector Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Host Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. Mexico Expression Vector Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Host Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Canada Expression Vector Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Host Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User

9. South America Expression Vector Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Host Type
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Expression Vector Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Host Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Expression Vector Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Host Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Expression Vector Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Host Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Expression Vector Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Host Type
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Expression Vector Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Host Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Expression Vector Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Host Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Expression Vector Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Host Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Expression Vector Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Thermo Fisher Scientific, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Promega Corporation
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Agilent Technologies, Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Bio-Rad Laboratories Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. QIAGEN NV
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Merck KGaA
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. TAKARA HOLDINGS Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. GenScript Corp.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Quest Diagnostics Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Addgene, Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer